ReviewJournal of Cancer2019
Latest Overview of the Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: The Past, the Present and the Future.
Review in Journal of Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Hormone, Targeted, and Combinational Therapies for Breast Cancers: From Humans to Dogs.International journal of molecular sciences · 2024Pooled it
- LRRC32 Mediates Resistance to Everolimus in Hormone Receptor-Positive, HER2-Negative Breast Cancer.Cancer management and research · 2026Article
- Association Between CDK4/CDK6 Expression and Prognosis in Patients with Adenocarcinoma of Gastroesophageal Junction.Digestive diseases and sciences · 2025Article
- Association of microtubule-based processes gene expression with immune microenvironment and its predictive value for drug response in oestrogen receptor-positive breast cancer.Frontiers in immunology · 2025Article
- Role of Radiology in the Diagnosis and Treatment of Breast Cancer in Women: A Comprehensive Review.Cureus · 2024Review
- Effects of combined use of ribociclib with PARP1 inhibitor on cell kinetics in breast cancer.Oncology letters · 2024Article
- Multidimensional analysis to elucidate the possible mechanism of bone metastasis in breast cancer.BMC cancer · 2023Article
- Firing of Replication Origins Is Disturbed by a CDK4/6 Inhibitor in a pRb-Independent Manner.International journal of molecular sciences · 2023Article
- The Role of Thrombomodulin in Estrogen-Receptor-Positive Breast Cancer Progression, Metastasis, and Curcumin Sensitivity.Biomedicines · 2023Article
- Antioxidant Protection against Trastuzumab Cardiotoxicity in Breast Cancer Therapy.Antioxidants (Basel, Switzerland) · 2023Review
- Injectable Nano Drug Delivery Systems for the Treatment of Breast Cancer.Pharmaceutics · 2022Review
- Photoinduced free radical-releasing systems and their anticancer properties.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2022Article
- Clinicopathological characteristics and treatment outcomes of luminal B1 breast cancer in Taiwan.Journal of the Chinese Medical Association : JCMA · 2022Observational
- Baicalin regulates stem cells as a creative point in the treatment of climacteric syndrome.Frontiers in pharmacology · 2022Review
- Inducible deletion of CDK4 and CDK6 - deciphering CDK4/6 inhibitor effects in the hematopoietic system.Haematologica · 2021Article
- Ribociclib-Induced Pneumonitis: A Case Report.Breast care (Basel, Switzerland) · 2021Article
- Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.Signal transduction and targeted therapy · 2021Review
- Current State of Breast Cancer Diagnosis, Treatment, and Theranostics.Pharmaceutics · 2021Review
- Global Trend in Research and Development of CDK4/6 Inhibitors for Clinical Cancer Therapy: A Bibliometric Analysis.Journal of Cancer · 2021Article
- Exploring treatment with Ribociclib alone or in sequence/combination with Everolimus in ERBMC cancer · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endocrine resistance in hormone receptor positive breast cancer patients urges us to develop novel approaches such as inhibitors of the cyclin-dependent kinases (CDK) 4/6 to reverse its resistance. Nowadays, three selective CDK4/6 inhibitors (Palbociclib, Ribociclib and Abemaciclib) are approved by Federal Drug Administration and the European Medicines Agency for the treatment of advanced and metastatic HR+/HER2- breast cancer. However, no consistent conclusion has been reached to its application in other types of breast cancer. Therefore, the purpose of our study was to overview the clinical trials about the beneficial effects of Palbociclib, Ribociclib and Abemaciclib in breast cancer with their tolerable adverse effects, and discuss their resistant mechanisms thus looking for useful biomarkers to predict the efficiency of the CDK4/6 inhibitors. The CDK4/6 inhibitors application after the support of preclinic and clinic data will be helpful to provide other alternatively suitable strategies for different types of breast cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.